BIOMERICA INC
BMRABioMerica Inc (BMRA) is a biotechnology company specializing in the development, manufacturing, and distribution of specialty pharmaceuticals and biopharmaceuticals. The company focuses on providing innovative solutions for clinical research, diagnostic testing, and therapeutic applications, serving healthcare providers, researchers, and pharmaceutical companies worldwide.
Company News
Biomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Me...
Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.
The global injection molding market is projected to reach $418.39 billion by 2031, driven by growing demand from the automotive and packaging industries. Metal injection molding is expected to see the highest growth rate during the forecast period.
Biomerica reported a modest 1% increase in total revenue for fiscal year 2024, with a 5% increase in core revenue excluding COVID-19 tests. The company implemented a significant cost-savings plan and reduced its net loss by 15%. Key milestones included FDA clearance for its Hp Detect Stool Antigen ELISA test and progress in the inFoods IBS pilot ...
IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.
